A peptide antagonist of the TLR4-MD2 interaction.

ABSTRACT: Toll-like receptors are an integral part of innate immunity in the central nervous system (CNS); they orchestrate a robust defense in response to both exogenous and endogenous danger signals. Recently, toll-like receptor 4 (TLR4) has emerged as a therapeutic target for the treatment of CNS-related diseases such as sepsis and chronic pain. We herein report a chemical biology approach by using a rationally designed peptide inhibitor to disrupt the TLR4-MD2 association, thereby blocking TLR4 signaling.

SUBMITTER: Slivka PF 

PROVIDER: S-EPMC2982775 | biostudies-literature | 2009 Mar

REPOSITORIES: biostudies-literature